|
Synonym(s):
|
M.
tuberculosis complex drug susceptibility test (DST), PZA DST
|
|
Requisition Form
|
G-MYCO
|
|
Test Description
|
Susceptibility
test to Pyrazinamide @ 100.0 µg/mL by MGIT drug susceptibility test method
|
|
Pre-Approval Needed
|
N/A
|
|
Supplemental
Information Required
|
N/A
|
|
Supplemental Form(s)
|
N/A
|
|
Performed on
Specimens from (sources)
|
Pure
isolate from human sources
|
|
Sample/Specimen Type
for Testing
|
M.
tuberculosis complex pure isolate in liquid or on solid culture medium
|
|
Minimum Volume/Size
Required
|
- Liquid
culture - 2.0 mL
- Solid
culture - Visible growth, more than a single colony
|
|
Storage/Preservation
Prior to Shipping
|
Ambient
|
|
Transport Medium
|
N/A
|
|
Specimen Labeling
|
- Two patient-specific identifiers required (e.g., patient full name, date of birth, Medical record number)
- Identifiers on specimen must exactly match submission form.
|
|
Shipping and Specimen
Handling Requirements
|
- Ship according to Dangerous Goods Regulations,
IATA, and/or CFR 49
- Category
A shipping applies
|
|
Method
|
MGIT drug susceptibility
test interpreted as either susceptible or resistant to a specific drug at
critical concentration recommended by CLSI
|
|
Turn-around Time
|
21
days
|
|
Interferences/Limitations
|
- Test
can only be performed on pure cultures of M. tuberculosis complex
|
|
Common Causes for Rejection
|
- Non-viable
isolates
- Cultures
overgrown by contaminating organisms
- Isolate
not M. tuberculosis complex
|
|
Additional
Information
|
- Isolates submitted for this test will be
identified by this laboratory. No fee
will be charged for this identification unless identification is requested on
the G-MYCO requisition form.
- This laboratory will notify submitter of new drug
resistance detected by this test.
|